Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Case report

Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report

Gianpiero Fasola*, Fabio Puglisi, Alessandro Follador, Marianna Aita, Silvia Di Terlizzi and Ornella Belvedere

Author affiliations

Dept. of Medical Oncology, University Hospital, P.le S. M. Misericordia, 33100 Udine, Italy

For all author emails, please log on.

Citation and License

BMC Cancer 2006, 6:289  doi:10.1186/1471-2407-6-289

Published: 18 December 2006

Abstract

Background

To date, there is no standard treatment for unresectable malignant peritoneal mesothelioma; either best supportive care or systemic chemotherapy with palliative intent are accepted options.

Case presentation

Here, we report the case of a 79-year old patient with malignant peritoneal mesothelioma who was treated with pemetrexed single-agent and obtained an impressive long-lasting response.

Conclusion

Single-agent pemetrexed is a treatment option for malignant peritoneal mesothelioma in selected elderly patients or in patients with unpaired performance status.